Monopar Therapeutics MNPR Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $0— | $0— | $0— | $0— | $0— | ||
| $11.75M+18.6% | $9.9M-37.7% | $15.89M+11.2% | $14.28M+4.4% | $13.68M+5.2% | ||
| $6.96M+2.3% | $6.8M+18.6% | $5.74M+18.9% | $4.82M+21.3% | $3.98M+26.0% | ||
| $18.71M+12.0% | $16.7M-22.7% | $21.62M+13.2% | $19.11M+8.2% | $17.66M+9.3% | ||
| $18.71M+12.0% | $16.7M-22.7% | $21.62M+13.2% | $19.11M+8.2% | $17.66M+9.3% | ||
| -$18.71M-12.0% | -$16.7M+22.7% | -$21.62M-13.2% | -$19.11M-8.2% | -$17.66M-9.3% | ||
| $3.72M+24.6% | $2.99M+36.9% | $2.18M+34.2% | $1.63M+77.0% | $918.7K+127% | ||
| -$14.98M-9.2% | -$13.72M+29.4% | -$19.44M-12.3% | -$17.31M-4.5% | -$16.57M-6.3% | ||
| -$1.93-4.3% | -$1.85+53.3% | -$3.96-2.9% | -$3.85+3.5% | -$3.99+3.2% | ||
| 30.1M+5.4% | 28.5M+14.5% | 24.9M+16.9% | 21.3M+19.6% | 17.8M+27.1% | ||
| -$14.86M-9.6% | -$13.56M+29.9% | -$19.36M-12.7% | -$17.18M-3.9% | -$16.54M-6.4% | ||
| -$3.99K-55.8% | -$2.56K— | —— | —— | —— | ||
| $124.29K-21.0% | $157.32K+77.4% | $88.68K-31.8% | $130.02K+339% | $29.64K-38.9% | ||
| -$18.71M-12.0% | -$16.7M+22.7% | -$21.62M-13.2% | -$19.11M-8.2% | -$17.66M-9.3% | ||
| -$18.71M-12.0% | -$16.7M+22.7% | -$21.62M-13.2% | -$19.11M-8.2% | -$17.66M-9.3% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- Is Monopar Therapeutics profitable?
- Monopar Therapeutics is not currently profitable: it reported a net loss of $15.0M over the trailing twelve months.
- Where does Monopar Therapeutics's income statement data come from?
- Every line is extracted from Monopar Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.